NGS e nuove tecnologie per il riposizionamento di farmaci e la terapia di precisione

TREATMENT OF BETA-THALASSEMIA PATIENTS WITH RAPAMYCIN (SIROLIMUS): FROM PRE-CLINICAL RESERCH TO A CLINICAL TRIAL

Linfociti T memoria ricircolanti dalla cute nelle comorbidità associate a psoriasi: prospettive prognostiche e terapeutiche

A personalized medicine approach for beta-thalassemia patients: testing sirolimus in a first pilot clinical trial (sirthalaclin)

Development of microRNA based protocols for detection of autologous blood transfusion in sport

Revealing the microRNA-transcription factors network in cystic fibrosis:from microRNA therapeutics to precision medicine (CF-miRNA-THER) FFC 7/2018

Titolo del progetto: MicroRNA Therapeutics in CF: Targeting CFTR and inflammation networks (MicroRNA-CF)

MicroRNA Therapeutics in CF: Targeting CFTR and inflammation networks (MICRORNA-CF)”

Ultra sensitive plasmonic devices for early cancer diagnosis

Novel molecular biomarkers for detection of autologous blood transfusion in sport: fetal hemoglobin and microRNAs.

Design and synthesis of improved analogs of trimethylangelicin (TMA) for personalized treatment of cystic fibrosis

Design and synthesis of improved analogs of trimethylangelicin (TMA) for personalized treatment of cystic fibrosis. Durata: 12 mesi (dal 01/09/2014 al 31/08/2015) Progetto n°: FFC#8/2014. Finanziato da: Fondazione per la ricerca sulla Fibrosi Cistica-Bando 2014

Fetal haemoglobin (HbF) induction as a strategy to improve life quality in thalassemia: characterisation of HbF inducing products and preclinical models to predict therapeutic response

Thalassaemia modular stratification system for personalized therapy of beta-thalassemia (THALAMOSS). Durata: 48 mesi (dal 01/11/2011 al 31/12/2015). Progetto n°: 306201. Finanziato da: FP7-HEALTH-2012-INNOVATION-1

THALAssaemia MOdular Stratification System for personalized therapy of beta-thalassemia

Peptide nucleic acids targeting oncomiR and tumor-suppressor miRNAs: cancer diagnosis and therapy. Durata: 36 mesi (dal 02/01/2013 al 02/01/2016). Progetto n°: IG13575. Finanziato da: AIRC 2012.

Hemoglobin production in beta-thalassemia erythroid cells following alteration of biomolecular pathways regulating globin gene expression. Durata: 24 mesi (dal 26/11/2010 al 26/11/2012). Progetto n°: GGP10214. Finanziato da: TELETHON 2010.